Drug class

Diet Aids

"Diet Aids" is an informal, consumer-oriented category rather than a formal, standard therapeutic drug class recognized by regulatory bodies like the FDA. Read more about Diet Aids

66 drugs in this class 32 manufacturers

Advertisement

Drugs in Diet Aids

Showing 28–36 of 66 drugs

PHENTERMINE HCL

AMPHETAMINES/ANOREXIANTS/STIMULANTS · WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER) ·+1
EPIC PHARMA LLC

BENZPHETAMINE HCL

AMPHETAMINES/ANOREXIANTS/STIMULANTS · WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER)
A-S MEDICATION

DIETHYLPROPION HCL

AMPHETAMINES/ANOREXIANTS/STIMULANTS · WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER)
A-S MEDICATION

PHENDIMETRAZINE TARTRATE

AMPHETAMINES/ANOREXIANTS/STIMULANTS · WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER)
A-S MEDICATION

PHENTERMINE HCL

AMPHETAMINES/ANOREXIANTS/STIMULANTS · WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER) ·+1
A-S MEDICATION

WEGOVY (semaglutide)

DIET AIDS · WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER) ·+3
A-S MEDICATION

PHENTERMINE HCL

AMPHETAMINES/ANOREXIANTS/STIMULANTS · WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER) ·+1
DIRECT RX

DIETHYLPROPION HCL

AMPHETAMINES/ANOREXIANTS/STIMULANTS · WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER)
CHARTWELL RX LL
Filter & compare in the drug finder → Opens the drug finder with Diet Aids preselected. Add indication or manufacturer filters there.

About Diet Aids.

"Diet Aids" is an informal, consumer-oriented category rather than a formal, standard therapeutic drug class recognized by regulatory bodies like the FDA.

In medical practice and clinical pharmacology, these agents are formally classified as anti-obesity agents, anorexiants, or weight-loss medications.

They promote weight reduction through diverse mechanisms, including central nervous system appetite suppression, stimulation of satiety pathways via incretin mimetics, or inhibition of gastrointestinal fat absorption.

These products are primarily indicated for chronic weight management in clinical obesity or overweight associated with metabolic and cardiovascular comorbidities.